Dr. Wang is currently Chief Operating Office of Beijing Shenogen Pharma Group Ltd. And previously the President of Novo Nordisk Research Center China, the first R&D center set up by a global pharmaceutical company in China. 

Baoping received a BS degree in Applied Chemistry from Shanghai Jiao Tong University in 1982, and a PhD in Genetics from University of Minnesota in 1990. He did his postdoc research at Harvard Medical School where he then served sequentially as an Instructor and Assistant Professor. His research area focused on molecular and cellular immunology.

Baoping joined industry when he returned China in 1998 to head a health care group in Novo Nordisk China R&D center. In 2001, Novo Nordisk established a new R&D center based on the health care group, Baoping was the head of the center since its founding. From April 2007, Baoping also served as a Vice President of Novo Nordisk R&D, and from January 2011 through July 2018, as President of Novo Nordisk Research Center China. He has joined Beijing Shenogen Pharma Group Ltd. as Chief Operating Office from August 2018. 

教育背景

1978-1982  上海交通大学应用化学系 高分子材料专业 获工学学士学位

1983-1990   美国明尼苏达大学生物学院遗传与细胞生物系分子免疫学专业 获博士学位

职业经历

1990-1991 哈佛医学院病理系及Dana Farber癌症研究所分子免疫学室 博士后

1991-1995哈佛医学院医疗系及 Beth Israel医院免疫学室 博士后

1995-1997  哈佛医学院医疗系及 Beth Israel医院免疫学室 讲师

1998.1-1998.8  哈佛医学院医疗系及 Beth Israel医院免疫学室 助理教授

1998.8-2001.8  诺和诺德（中国）研究发展中心 助理总监

2001.9-2007.3 诺和诺德中国研究发展中心研究总监

2007.4-2011.1  诺和诺德中国研发中心总经理，诺和诺德研发部付总裁

20011.1-2018.7  诺和诺德中国研发中心总裁

20018.8-    北京盛诺基医药科技有限公司，首席运营官